DigestRedComo funciona
Red
/
Empresas
AI
No verificado

AIM ImmunoTech Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaOncologíaSaludVIH, SIDA y enfermedades autoinmunes

14 Comunicados de prensa

Ver todos los comunicados de prensa
03/11/2025
Biotecnología
Legislación/Derecho/Fiscalidad
Medicina Salud Bienestar
AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue
Fuente
AIM ImmunoTech Inc.
Editor
GLOBENEWSWIRE
1.00
0
04/09/2025
Biotecnología
Medicina Salud Bienestar
AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland
Fuente
AIM ImmunoTech Inc.
Editor
GLOBENEWSWIRE
1.00
0
28/02/2025
Biotecnología
Anuncios breves
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
Fuente
AIM ImmunoTech Inc.
Editor
GLOBENEWSWIRE
1.00
0
17/12/2024
Oncología
Salud
VIH, SIDA y enfermedades autoinmunes
Biotecnología
Medicina - Varios
Farmacéutica
AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting
Fuente
AIM ImmunoTech Inc.
Editor
Business Wire
1.00
0
16/12/2024
Ciencia
Finanzas
Medicina - Varios
Asociaciones/Profesionales
Biotecnología
Salud
Farmacéutica
Oncología
AIM ImmunoTech Reminds Shareholders to Vote “FOR” All Four Incumbent Board Members on the WHITE Universal Proxy Card
Fuente
AIM ImmunoTech Inc.
Editor
Business Wire
1.00
0
12/12/2024
Ciencia
Finanzas
Biotecnología
Medicina - Varios
Asociaciones/Profesionales
Farmacéutica
Salud
Oncología
AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board Members
Fuente
AIM ImmunoTech Inc.
Editor
Business Wire
1.00
0
12/12/2024
Biotecnología
Anuncios breves
AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue
Fuente
AIM ImmunoTech Inc.
Editor
GLOBENEWSWIRE
1.00
0
10/12/2024
Oncología
Salud
VIH, SIDA y enfermedades autoinmunes
Sanidad
Farmacéutica
Biotecnología
Glass Lewis Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell
Fuente
AIM ImmunoTech Inc.
Editor
Business Wire
1.00
0
05/12/2024
Ciencia
Finanzas
Medicina - Varios
Asociaciones/Profesionales
Biotecnología
Farmacéutica
Salud
Oncología
ISS Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan and Dr. William M. Mitchell
Fuente
AIM ImmunoTech Inc.
Editor
Business Wire
1.00
0
02/12/2024
Biotecnología
VIH, SIDA y enfermedades autoinmunes
Salud
Farmacéutica
Oncología
AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group’s Nominees to the Board
Fuente
AIM ImmunoTech Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0